Apogee Therapeutics, Inc. (APGE)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$135.07-0.01%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put APGE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisModerate volatility — typically moves about 0% a day.
View RiskNot enough reads yet
APGE rests on its future business growth, but the desk gives no revenue trend. The company was unprofitable over the past year, with weak recent performance. Its latest quarter missed consensus, with reported GAAP EPS of -1.14. The desk omits valuation multiples and priced-in expectations, so that comparison is unavailable. Our model puts the next-quarter miss probability near 43%. The thesis remains intact, and the read is provisional.
Trailing returns as of 2026-09-02. APGE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering APGE (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare APGE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| APGE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put APGE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete acquisition by AbbVie
Financing supports acquisition, enhancing strategic alignment.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-02. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Begin Phase 3 trials of zumilokibart
Phase 3 trials for zumilokibart are a key objective.
Advances: Begin Phase 3 trials of zumilokibart
Progress on pivotal trial for eczema supports product development.
CEO stock sale raises concerns about insider confidence.
Advances: Begin Phase 3 trials of zumilokibart
Positive trial outlook boosts confidence in Phase 3.